Skip to content
10-Q

Quarterly Report

Reviva Pharmaceuticals Holdings, Inc. RVPH

0001437749-25-026967

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 11, 2025 68M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$13.21M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$20.2M
Short Term Debt Q2 2025 · Jun 30, 2025 $113.25K
Short Term Debt Q2 2025 · Dec 31, 2024 $458.15K
Cash And Equivalents Q2 2025 · Jun 30, 2025 $10.36M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $13.48M
Stockholders Equity Q2 2025 · Jun 30, 2025 −$459.15K
Stockholders Equity Q2 2025 · Mar 31, 2025 −$4.46M
Stockholders Equity Q2 2025 · Dec 31, 2024 $812.57K
Stockholders Equity Q2 2025 · Jun 30, 2024 −$6.04M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$1.35M
Stockholders Equity Q2 2025 · Dec 31, 2023 $5.72M
Current Liabilities Q2 2025 · Jun 30, 2025 $12.08M
Current Liabilities Q2 2025 · Dec 31, 2024 $14.6M
Total Liabilities Q2 2025 · Jun 30, 2025 $12.09M
Total Liabilities Q2 2025 · Dec 31, 2024 $14.69M
Current Assets Q2 2025 · Jun 30, 2025 $10.82M
Current Assets Q2 2025 · Dec 31, 2024 $14.68M
Total Assets Q2 2025 · Jun 30, 2025 $11.63M
Total Assets Q2 2025 · Dec 31, 2024 $15.5M
Eps Basic Q2 2025 · Jun 30, 2025 −$0.12
Eps Basic Q2 2025 · Jun 30, 2025 −$0.25
Eps Basic Q2 2025 · Jun 30, 2024 −$0.26
Eps Basic Q2 2025 · Jun 30, 2024 −$0.51
Sga Expense Q2 2025 · Jun 30, 2025 $2.35M
Sga Expense Q2 2025 · Jun 30, 2025 $4.77M
Sga Expense Q2 2025 · Jun 30, 2024 $2.55M
Sga Expense Q2 2025 · Jun 30, 2024 $4.68M
Rd Expense Q2 2025 · Jun 30, 2025 $3.72M
Rd Expense Q2 2025 · Jun 30, 2025 $7.84M
Rd Expense Q2 2025 · Jun 30, 2024 $5.58M
Rd Expense Q2 2025 · Jun 30, 2024 $11.37M
Net Income Q2 2025 · Jun 30, 2025 −$6.05M
Net Income Q2 2025 · Jun 30, 2025 −$12.49M
Net Income Q2 2025 · Jun 30, 2024 −$7.86M
Net Income Q2 2025 · Jun 30, 2024 −$15.29M
Operating Income Q2 2025 · Jun 30, 2025 −$6.07M
Operating Income Q2 2025 · Jun 30, 2025 −$12.61M
Operating Income Q2 2025 · Jun 30, 2024 −$8.13M
Operating Income Q2 2025 · Jun 30, 2024 −$16.05M